Effect of Pravastatin on Serum Lipids of Patient with Primary Hyperlipidemia.
10.4070/kcj.1990.20.1.128
- Author:
Won sang YOO
;
Won Sub KOH
;
Byoung Yul CHO
;
Suck Koo CHOI
- Publication Type:Original Article
- Keywords:
Pravastatin;
HMG CoA reductase inhibitor;
Hyperlipidemia
- MeSH:
Cholesterol;
Cholesterol, LDL;
Coenzyme A;
Exanthema;
Humans;
Hyperlipidemias*;
Oxidoreductases;
Pravastatin*;
Triglycerides
- From:Korean Circulation Journal
1990;20(1):128-134
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
A new hypolipidemic drug, pravastatin, hydroxymethylglutaryl coenzyme A reductase inhibitor was administered to 33 patients with primary hyperlipidemia, 10mg daily for 8 weeks and sequential changes of lipid profile were analysed as follows. 1) Mean value at baseline period of total cholesterol, triglyceride, high and low density lipoprotein cholesterol were 260, 220, 51 and 163mg/dl respectively. 2) Total cholesterol showed 21% decrease at the end of 8 weeks and that of LDL-cholesterol were 30%. 3) Triglyceride decreased 16% at the end of 8 weeks and increment of HDL-cholesterol was 8% at the end of 8 weeks. 4) No serious side reactions were observed except one patient, who showed generalized skin rash which last 3 days and did not prevent further medication. In conclusion, pravastatin is a safe and useful hypolipidemic agent for the patient with primary hyperlipidemia.
